My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

112.14 +0.41 (+0.37%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

July 10, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharma Gets Price-Target Bump Ups To $129 After Oral Obesity Drug Impresses In Phase 2; Retail Appetite Swells ↗

July 10, 2025

Analysts from Wells Fargo, Stifel, and others raised their targets following the release of strong BMI reduction data for bivamelagon.

Via Stocktwits

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

July 09, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Here's How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years ↗

June 05, 2025

Via Benzinga

12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know ↗

May 29, 2025

Via Benzinga

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

July 09, 2025

Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Rhythm Pharma's Oral Drug For Rare Obesity Shows Promise ↗

July 09, 2025

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 with regulators.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 09, 2025

Via Benzinga

These stocks are moving in today's session ↗

July 09, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity ↗

July 09, 2025

Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity.

Via Stocktwits

Topics Government

Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity ↗

July 09, 2025

Rhythm Pharmaceuticals shares surged to a record high Wednesday on promising results for a drug that could treat obesity.

Via Investor's Business Daily

Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday ↗

July 09, 2025

Via Benzinga

Which stocks are gapping on Wednesday? ↗

July 09, 2025

The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity

July 09, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Wondering what's happening in today's after-hours session? ↗

July 08, 2025

As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity

July 08, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

8 Analysts Have This To Say About Rhythm Pharmaceuticals ↗

June 26, 2025

Via Benzinga

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

June 25, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗

May 22, 2025

RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) meets Minervini’s Trend Template with strong technicals and high revenue growth, making it a candidate for growth investors.

Via Chartmill

Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program

May 14, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) ↗

May 07, 2025

Via Benzinga

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

May 07, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

May 06, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

April 23, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio? ↗

April 13, 2025

Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty.

Via Benzinga

Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday ↗

April 08, 2025

Via Benzinga

Ross Stores To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

April 08, 2025

Via Benzinga

Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish ↗

April 07, 2025

CEO David Meeker said the company is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025.

Via Stocktwits

Topics Government

Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder ↗

April 07, 2025

Rhythm's Phase 3 trial shows setmelanotide significantly reduced BMI in rare hypothalamic obesity without new safety concerns over 52 weeks.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.